Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Retinal degeneration protein 3 (RD3)
- Target
- RD3
- Molecular classification
- Other (RD3 is a regulatory protein; it does not fit standard druggable target classes such as receptor, ion channel, enzyme, or transporter), Protein coding gene product
01
Overview
Retinal degeneration protein 3 (RD3) is a small regulatory protein, encoded by the RD3 gene on chromosome 1, that is essential for the function and survival of photoreceptor cells in the retina. RD3 directly inhibits the activity of retinal guanylyl cyclases (RetGC1/2; GUCY2D/2F), which produce cyclic GMP (cGMP), and also facilitates the trafficking of these cyclases to the photoreceptor outer segments. Additionally, RD3 upregulates GUK1, a kinase involved in GMP/cGMP recycling. Mutations in RD3 cause Leber congenital amaurosis type 12 (LCA12), a severe inherited blindness, by preventing regulation of cGMP metabolism and impairing photoreceptor survival. RD3 does not belong to standard molecular target families (such as receptors or enzymes) and is not the target of approved drugs; its primary relevance is genetic and as a regulator of photoreceptor biochemistry.
- Other names
- RD3C1orf36LCA12Protein RD3Retinal degeneration 3GUCY2D regulatorRetinal degeneration protein 3
02
Biological functions
Inhibits the activity of retinal guanylyl cyclases (GUCY2D/RetGC1 and GUCY2F/RetGC2)Facilitates transport of guanylyl cyclases to photoreceptor outer segmentsEssential for survival of rod and cone cells in the retinaUpregulates GUK1 kinase, involved in GMP/cGMP recycling
03
Disease associations
Inherited retinal dystrophiesLeber congenital amaurosis (LCA12), due to RD3 mutationsOther congenital blindness/vision disorders associated with RD3 deficiency
04
Safety considerations
Gene therapy or protein replacement for RD3 deficiency presents challenges due to its essential role in photoreceptor survival; off-target effects would risk additional retinal degenerationLoss of RD3 function causes severe congenital blindness
05
Biomarkers
RD3 gene mutations are genetic biomarkers for diagnosing LCA12 and related congenital retinal degenerations
Beyond the preview
Go deeper on Retinal degeneration protein 3 (RD3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Retinal degeneration protein 3 (RD3).